Regeneron Pharmaceuticals 83rd in Trading Volume as Stock Drops for Third Day

On June 5, 2025, Regeneron Pharmaceuticals, Inc. (REGN) closed with a trading volume of $866 million, ranking 83rd in the day's stock market. The stock price decreased by 0.38%, marking the third consecutive day of decline, with a total decrease of 1.58% over the past three days.

Regeneron Pharmaceuticals, Inc. has entered into a licensing agreement with Hansoh Pharma to acquire the rights to HS-20094, a GLP-1/GIP receptor agonist currently in advanced stages of clinical development. This agreement aims to enhance Regeneron's pipeline for obesity and metabolic treatments.

This strategic move by Regeneron is expected to bolster its position in the competitive pharmaceutical market, particularly in the areas of obesity and metabolic disorders. The acquisition of HS-20094, which is a GLP-1/GIP receptor agonist, aligns with Regeneron's ongoing efforts to develop innovative therapies that address unmet medical needs.